[Stock in Focus] Sam Chun Dang Pharm Up 9% on 'Wegovy Oral' Contract with 11 European Countries

The stock price of Sam Chun Dang Pharm, which has signed an exclusive contract for the oral anti-obesity drug 'Wegovy Oral' with 11 European countries, has risen for two consecutive days.

As of 10:15 a.m. on February 27, Sam Chun Dang Pharm is trading at 829,000 won, up 9.51% (72,000 won). This marks a two-day rally following the upper price limit close the previous day.

The previous day, Sam Chun Dang Pharm announced that it had signed an exclusive license and commercialization agreement with a European pharmaceutical company for the generic versions of the oral diabetes treatment Rybelsus and the oral anti-obesity drug Wegovy Oral (semaglutide) covering 11 countries including the United Kingdom.

The total amount for the upfront payment and milestone payments is 30 million euros (approximately 5.08 billion won). Product supply will continue for 10 years from the first sale date and will be automatically renewed every 5 years thereafter. Net profits will be settled quarterly, with Sam Chun Dang Pharm receiving 60% and the partner company receiving 40%.

However, the disclosure of the partner company and the detailed terms regarding the upfront payment and milestones has been deferred until February 25, 2036, to protect the partner's business strategy.

This content was produced with the assistance of AI translation services.